American heart journal plus : cardiology research and practice · 2026
Long-term cardiovascular risk with cardiovascular-kidney-metabolic syndrome in U.S adults.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Essa Mohammed, Malik Devesh, Lu Yuan, Yang Huanhuan, Spatz Erica S, Krumholz Harlan M, Faridi Kamil F
Аннотация
BACKGROUND: Cardiovascular-kidney-metabolic (CKM) syndrome staging helps identify cardiovascular disease (CVD) risk. Determining how predicted CVD risks vary across CKM stages in the U.S can further improve understanding of disease progression and help guide prevention strategies.
METHODS: We analyzed 2011-2020 NHANES data using survey-weighted quantile regression to compare total CVD risks predicted by the PREVENT equations across CKM stages.
RESULTS: Among 12,349 CVD-free adults aged 30-79 (∼122.8 million adults), median (25th - 75th) 10-year and 30-year CVD risks were 0.9% (0.5-2.1%) and 6.0% (3.3-10.1%) in Stage 0, 1.5% (0.7-3.3%) and 8.9% (4.7-14.9%) in Stage 1, 4.6% (2.0-9.2%) and 18.4% (0.4-26.3%) in Stage 2, and 23.5% (21.3-27.1%) and 51.6% (38.3-58.6%) in Stage 3 CKM, respectively. Higher CKM stage generally predicted higher CVD risks. Men had higher risks than women, while race/ethnicity differences were modest.
CONCLUSION: CVD risks estimated by PREVENT equations increase with higher CKM stage, supporting CKM staging for risk stratification.
METHODS: We analyzed 2011-2020 NHANES data using survey-weighted quantile regression to compare total CVD risks predicted by the PREVENT equations across CKM stages.
RESULTS: Among 12,349 CVD-free adults aged 30-79 (∼122.8 million adults), median (25th - 75th) 10-year and 30-year CVD risks were 0.9% (0.5-2.1%) and 6.0% (3.3-10.1%) in Stage 0, 1.5% (0.7-3.3%) and 8.9% (4.7-14.9%) in Stage 1, 4.6% (2.0-9.2%) and 18.4% (0.4-26.3%) in Stage 2, and 23.5% (21.3-27.1%) and 51.6% (38.3-58.6%) in Stage 3 CKM, respectively. Higher CKM stage generally predicted higher CVD risks. Men had higher risks than women, while race/ethnicity differences were modest.
CONCLUSION: CVD risks estimated by PREVENT equations increase with higher CKM stage, supporting CKM staging for risk stratification.